Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia

Justin Watts, Bogdan Dumitriu, Patrick Hilden, Ashwin Kishtagari, Franck Rapaport, Christina Chen, Jihae Ahn, Sean M. Devlin, Eytan M. Stein, Raajit Rampal, Ross L. Levine, Neal Young, Martin S. Tallman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies.

Original languageEnglish (US)
Pages (from-to)62-65
Number of pages4
JournalLeukemia Research
Volume49
DOIs
StatePublished - Oct 1 2016

Fingerprint

Telomere
Acute Myeloid Leukemia
Mutation
Epigenomics
Biomarkers
Survival
Enzymes

Keywords

  • Acute myeloid leukemia
  • Clinical outcomes
  • Somatic mutations
  • Telomere length

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. / Watts, Justin; Dumitriu, Bogdan; Hilden, Patrick; Kishtagari, Ashwin; Rapaport, Franck; Chen, Christina; Ahn, Jihae; Devlin, Sean M.; Stein, Eytan M.; Rampal, Raajit; Levine, Ross L.; Young, Neal; Tallman, Martin S.

In: Leukemia Research, Vol. 49, 01.10.2016, p. 62-65.

Research output: Contribution to journalArticle

Watts, J, Dumitriu, B, Hilden, P, Kishtagari, A, Rapaport, F, Chen, C, Ahn, J, Devlin, SM, Stein, EM, Rampal, R, Levine, RL, Young, N & Tallman, MS 2016, 'Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia', Leukemia Research, vol. 49, pp. 62-65. https://doi.org/10.1016/j.leukres.2016.07.013
Watts, Justin ; Dumitriu, Bogdan ; Hilden, Patrick ; Kishtagari, Ashwin ; Rapaport, Franck ; Chen, Christina ; Ahn, Jihae ; Devlin, Sean M. ; Stein, Eytan M. ; Rampal, Raajit ; Levine, Ross L. ; Young, Neal ; Tallman, Martin S. / Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. In: Leukemia Research. 2016 ; Vol. 49. pp. 62-65.
@article{4bcb743e174c487a9b0f669d549b3f9b,
title = "Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia",
abstract = "We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies.",
keywords = "Acute myeloid leukemia, Clinical outcomes, Somatic mutations, Telomere length",
author = "Justin Watts and Bogdan Dumitriu and Patrick Hilden and Ashwin Kishtagari and Franck Rapaport and Christina Chen and Jihae Ahn and Devlin, {Sean M.} and Stein, {Eytan M.} and Raajit Rampal and Levine, {Ross L.} and Neal Young and Tallman, {Martin S.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.leukres.2016.07.013",
language = "English (US)",
volume = "49",
pages = "62--65",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia

AU - Watts, Justin

AU - Dumitriu, Bogdan

AU - Hilden, Patrick

AU - Kishtagari, Ashwin

AU - Rapaport, Franck

AU - Chen, Christina

AU - Ahn, Jihae

AU - Devlin, Sean M.

AU - Stein, Eytan M.

AU - Rampal, Raajit

AU - Levine, Ross L.

AU - Young, Neal

AU - Tallman, Martin S.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies.

AB - We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies.

KW - Acute myeloid leukemia

KW - Clinical outcomes

KW - Somatic mutations

KW - Telomere length

UR - http://www.scopus.com/inward/record.url?scp=84983750725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983750725&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.07.013

DO - 10.1016/j.leukres.2016.07.013

M3 - Article

C2 - 27568819

AN - SCOPUS:84983750725

VL - 49

SP - 62

EP - 65

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -